This template is to be used as a guideline for developing procedures, protocols, and/or order sets around the use of ADASUVE® to ensure that REMS requirements are being met.

**INDICATION**
- Agitation associated with bipolar I disorder
- Agitation associated with schizophrenia

**PATIENT SCREENING**

PRIOR TO DOSING:
- Assess for acute respiratory symptoms
  - wheezing
  - cough
  - dyspnea
  - other: __________

- Assess for respiratory signs
  (include chest auscultation)
  - wheezing
  - other: __________

Inquire and/or check medical records for:
- current diagnosis or history of asthma, COPD, or other lung disease associated with bronchospasm
- current use of medications to treat airways disease, such as asthma or COPD
- history of bronchospasm following ADASUVE treatment
- known hypersensitivity (e.g., serious skin reaction) to loxapine or amoxapine

If any of the above screening is positive, DO NOT USE ADASUVE. ADASUVE is contraindicated in these patients.

**DOSE ADMINISTERED**

**TIME:** __________

Limit ADASUVE use to a single dose per patient within a 24-hour period.

**POST-TREATMENT OBSERVATION/MONITORING**

Patient must be monitored every 15 minutes for at least 1 hour after treatment for signs/symptoms of bronchospasm.

**MONITORING**

TIME:

- Heart rate (rate per minute): __________
- Respiratory rate (rate per minute): __________
- Chest auscultation (clear/other): __________
- Check for respiratory signs/symptoms
  - wheezing
  - cough
  - dyspnea
  - chest tightness
  - other: __________

TIME:

- Heart rate (rate per minute): __________
- Respiratory rate (rate per minute): __________
- Chest auscultation (clear/other): __________
- Check for respiratory signs/symptoms
  - wheezing
  - cough
  - dyspnea
  - chest tightness
  - other: __________

TIME:

- Heart rate (rate per minute): __________
- Respiratory rate (rate per minute): __________
- Chest auscultation (clear/other): __________
- Check for respiratory signs/symptoms
  - wheezing
  - cough
  - dyspnea
  - chest tightness
  - other: __________

**Note:** Treat bronchospasm with inhaled short-acting beta-agonist bronchodilator (e.g., albuterol) and other measures as clinically indicated.